Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02345265
Title Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

endometrioid ovary carcinoma

ovarian endometrial cancer

ovarian serous cystadenocarcinoma

fallopian tube endometrioid adenocarcinoma

peritoneal serous adenocarcinoma

ovary serous adenocarcinoma

fallopian tube serous adenocarcinoma


Cediranib + Olaparib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.